Re: HPLC - Method development for impurities in drug product
Posted: Fri Apr 17, 2015 8:32 pm
Nice problem to be discussed here:D
Just some quick thoughts that came to my mind:
- Just to be sure that there are no undissolved excipients left, I'd add a filtration step via syringe filter. 0.45µm filters usually are fine, 0.20µm might be better to be on the safe side
- If anyhow possible, use your mobile phase as sample solvent (in the case of gradients, the initial mobile phase). You might prevent a lot of problems
- You wrote that your analytes of interest are similar to Boceprevir. Boceprevir has no ionazible groups. If the same is true for your analytes, you don't need any buffer or acid in your mobile phase. Good thing - your mobile phase is simpler. Bad thing - you loose the most powerful tool to tune separation selectivity, i.e. mobile phase pH. If, on the other hand, you impurities contain ionizible groups, you will see huge changes in selectivity when changing pH.
- For gradient separations, particle size of your stationary phase has much less impact on separation efficiency than with isocratic separations. If pressure is an issue, you might consider changing to a 5µm phase. With gradients, you usually don't loose that much efficiency.
- The columns you tested so far (ACE C18, XBridge C18, and YMC Pro C18) are all quite similar. They belong to the same group of very hydrophobic, well-endcapped columns. Therefore, chromatography usually will look quite similar on all of them. In your case, if it doesn't look good on ACE, chance is high it will not look much better on XBridge or YMC Pro. For REAL changes in column selectivity, you might want to look at different column chemistries, like polar-embedded C18s. And don't forget there other things than C18...
- It might me worth to try some other organic modifiers than just ACN and MeOH. THF and 2-propanole, for example, can give quite astonishing shifts in selectivity even when used in very small amounts.
Just some quick thoughts that came to my mind:
- Just to be sure that there are no undissolved excipients left, I'd add a filtration step via syringe filter. 0.45µm filters usually are fine, 0.20µm might be better to be on the safe side
- If anyhow possible, use your mobile phase as sample solvent (in the case of gradients, the initial mobile phase). You might prevent a lot of problems
- You wrote that your analytes of interest are similar to Boceprevir. Boceprevir has no ionazible groups. If the same is true for your analytes, you don't need any buffer or acid in your mobile phase. Good thing - your mobile phase is simpler. Bad thing - you loose the most powerful tool to tune separation selectivity, i.e. mobile phase pH. If, on the other hand, you impurities contain ionizible groups, you will see huge changes in selectivity when changing pH.
- For gradient separations, particle size of your stationary phase has much less impact on separation efficiency than with isocratic separations. If pressure is an issue, you might consider changing to a 5µm phase. With gradients, you usually don't loose that much efficiency.
- The columns you tested so far (ACE C18, XBridge C18, and YMC Pro C18) are all quite similar. They belong to the same group of very hydrophobic, well-endcapped columns. Therefore, chromatography usually will look quite similar on all of them. In your case, if it doesn't look good on ACE, chance is high it will not look much better on XBridge or YMC Pro. For REAL changes in column selectivity, you might want to look at different column chemistries, like polar-embedded C18s. And don't forget there other things than C18...
- It might me worth to try some other organic modifiers than just ACN and MeOH. THF and 2-propanole, for example, can give quite astonishing shifts in selectivity even when used in very small amounts.
